Figure 4 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Year: 2024
Type: other
Abstract: AT-0174, a dual TDO2/IDO1 inhibitor, decreases TRP catabolism in anchorage-independent TNBC cells expressing TDO2 or IDO1 and reduces both formyl-KYN or KYN. A, Schematic of experimental design. B and E, TRP; C and F, formyl-KYN; D and G, KYN levels in cells and conditioned media of MDA-MB-453 or BT549 following suspension culture with or without 1 µmol/L and 10 µmol/L of TDO2/IDO1 inhibitor AT-0174 treatment (H). BT549 shTDO2-98 (IDO1 comp) was treated with 10 µmol/L AT-0174, 10 µmol/L TDO2 inhibitor 680C91, or 10 µmol/L IDO1 inhibitor epacadostat. I, KYN levels of MDA-MB-231 treated with vehicle (DMSO) control, 10 µmol/L AT-0174, or 10 µmol/L epacadostat. All treatments above were conducted for 48 hours, and conditioned media were analyzed for TRP catabolites and shown as peak area. Data are displayed as mean ± SEM by one-way ANOVA analysis. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Language: English
Subfield: Biological Psychiatry
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4403467696